Parenteral Drugs (India) is currently trading at Rs. 125.50, up by 6.80 points or 5.73% from its previous closing of Rs. 118.70 on the BSE.
The scrip opened at Rs. 129.00 and has touched a high and low of Rs. 130.55 and Rs. 123.30 respectively. So far 31194 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 130.55 on 15-March-2013 and a 52 week low of Rs. 51.05 on 04-Jun-2012.
Last one week high and low of the scrip stood at Rs. 130.55 and Rs. 107.00 respectively. The current market cap of the company is Rs. 331.10 crore.
The promoters holding in the company stood at 69.29% while Institutions and Non-Institutions held 1.78% and 28.94% respectively.
Parenteral Drugs India’s one of the wholly owned subsidiaries (WOS) - Goa Formulations has executed an agreement with Fresenius Kabi India to sell its only pharmaceutical manufacturing unit at Goa at a consideration of Rs 200 crore, and the agreement has become binding on the parties. Further, Parenteral Drugs (India) has also accorded its consent to the transaction as the holding company.
Parenteral Drugs India is the pioneer company making 400 mg Ciprofloxacin infusion in 200 ml with 5% dextose. The I.V. fluids are packed in size ranging from 100 ml to 3 litre and dialysis solution up to 10 litres water for injection is manufactured with the help of hi-tech From-Fill-seal machine ranging from 1 ml to 10 ml.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1800.95 |
Dr. Reddys Lab | 1341.15 |
Cipla | 1468.10 |
Lupin | 2135.85 |
Zydus Lifesciences | 966.10 |
View more.. |